---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-047304"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:27:36.226325+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunome Q1 net loss $41.6M; cash $317.3M; varegacestat data expected H2 2025

## Summary
- Net loss of $41.6M for Q1 2025; R&D expense $36.9M, G&A $10.7M.
- Cash, equivalents and marketable securities $317.3M as of March 31, 2025; expected to fund operations into 2027.
- Phase 3 RINGSIDE trial of varegacestat fully enrolled; topline data expected in second half of 2025.
- Phase 1 for IM-1021 (ROR1 ADC) ongoing; IM-3050 (FAP radiotherapy) IND cleared, trial to start H2 2025.
- Amended 2024 Inducement Plan to increase reserved shares from 2M to 3.5M for new-hire equity grants.

## SEC filing metadata
- accession: 0001104659-25-047304
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/0001104659-25-047304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-047304
- JSON: https://secwatch.observer/filing/0001104659-25-047304.json
- Plain text: https://secwatch.observer/filing/0001104659-25-047304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.